secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-09-03T11:50:15+00:00
Accession:  0001193125-26-381060
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio reports positive CLYM116 Phase 1 data: ~29-day half-life, >90% APRIL suppression, Q12W dosing support
--------------------------------------------------------------------------------

- CLYM116 half-life ~29 days, 3x longer than sibeprenlimab; >90% free APRIL suppression after single 320 mg dose.
- Single 320 mg dose drove 60-75% suppression of IgA, Gd-IgA1, and IgM, maintained through 12 weeks.
- No serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia in 46-subject Phase 1 trial.
- Phase 2 NAVIGATE-2 (800 mg load, 400 mg Q8W/Q12W) ongoing; initial data expected H1 2027; Phase 3 initiation in 2027.
- High-concentration 200 mg/mL formulation enables 400 mg single SC injection; pre-filled syringe complete; autoinjector in development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/0001193125-26-381060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/d97033d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-381060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer